People

The People Running Blue Moon

Governance grade: C+. A capable founder-family at the top with enormous personal skin in the game, but concentrated control, a related-couple at the apex, and a questionable capital-allocation record since listing leave outside shareholders riding along rather than being protected.

1. The People Running This Company

Blue Moon is a family-run Chinese household-care champion wrapped in a Cayman holding structure. Five executive directors dominate the board; three independent non-executives fill the required listing-rule seats. The husband-and-wife founders make the decisions.

The capability read is genuinely good: Pan trained as an organic chemist, Luo as a chemical engineer, and between them they built Blue Moon from a small Guangzhou soap brand in 1992 into China's #1 liquid laundry detergent for sixteen straight years. What is missing is anyone on the board whose incentive is not to protect the founder family's value and reputation.

2. What They Get Paid

Blue Moon's results announcement discloses aggregate auditor's remuneration and aggregate employee benefit expense, but — as is standard for HKEX preliminary announcement format — does not print director-by-director emoluments. Those sit inside the full annual report. What we can see is the shape of compensation: share-based (not cash-heavy), concentrated in executive directors, and distributed against a backdrop of shareholder losses.

The 2022 Share Award Plan is effectively an executive-director-only plan. Of 119.6M share awards, all went to three executive directors of the listco (plus three directors of operating subsidiaries). At today's HK$2.96, 119.6M shares are worth roughly HK$354M (US$45M) — concentrated at the top. Separately, the 2021 plan spread 276.7M awards across 610 staff, broadly — a healthier pattern. The non-audit fee ratio to audit (~31%) is unremarkable and does not raise an auditor-independence flag.

Cash salary ratchets are muted in the disclosures. The real pay mechanism here is stock, delivered from a trust (Tricor Trust Hong Kong, ~4% of shares) that the company buys shares into. That is a dilution-neutral structure — good — but the lockup/vesting schedules are discretionary, which in a controlled company is a governance watch item even though the plan rules explicitly carve out executive-director self-approval.

3. Are They Aligned?

This is where the story is most interesting — and most uncomfortable. Alignment by ownership is overwhelming. Alignment by behaviour is mixed.

Ownership and control

Pan Dong's ~HK$12.8B (US$1.64B) stake is by far the dominant form of alignment. A family that has the bulk of its net worth in one stock has zero incentive to loot it — and that is the central governance asset here. At current prices, Pan's paper wealth is down materially from IPO levels: the stock is 77.5% below the HK$13.16 IPO price, and the group market cap has fallen from ~HK$85B at listing to HK$17.3B today — an ~80% capital destruction over five years. The chairman has felt this in her wallet. So have minority holders.

Dilution and buybacks

Share count is flat. Share awards are satisfied out of existing shares via the Tricor Trust, not newly issued stock. In 2025, only 987,850 shares were issued from option exercises (about 0.02% dilution). Dilution is not a governance problem at Blue Moon.

Capital allocation — the uncomfortable part

Between 2020 and 2024, selling and marketing spend grew 2.5x (HK$2.0B to HK$5.0B) while revenue grew only 22%. The board — controlled by insiders — approved a strategy that burned through HK$3B+ of shareholder capital in promotional spending (heavy livestreaming investment on Douyin and JD) that turned a HK$1.3B profit in 2020 into a HK$749M loss by 2024. Management is now pulling back (S&M down 11.5% in 2025, losses narrowing), but the question a governance analyst should ask is: what board made that call, and who held anyone accountable? The answer is that there was no independent force with enough weight to stop it.

Dividends — a shareholder-friendly pattern

The company resumed a HK$0.18/share dividend in 2025 (HK$0.08 interim + HK$0.10 final) after flattening it through the loss years. No share buyback programme was run — the company "did not purchase, sell or redeem any listed securities" in 2025 — which is a missed opportunity at the current depressed price but not a governance issue.

Related-party behaviour — muted

Balance-sheet related-party exposure is tiny: HK$412k owed to a related company as of year-end 2025 (essentially round-off). There is no evidence in the results announcement of meaningful related-party transactions, loans, or offtake arrangements. This is a clean item. The VIE-style concern often raised with Cayman-incorporated Chinese listcos applies here structurally (Cayman parent, PRC operating subs) but Blue Moon's business is entirely sale of physical goods to Chinese consumers — the VIE exposure is the common HK-listed Chinese issuer type, not the more fragile education or internet kind.

Skin-in-the-game score

7/10. A founding family with ~74% of the equity and ~US$1.6B at stake is deeply aligned. What drops it from 9 is (a) the alignment is to Pan Dong's capital preservation, not to minority holders' IRR — she can afford a 77% drawdown and still be a billionaire; (b) no meaningful recent insider open-market purchases to signal confidence at the bottom; (c) the 2022 ED-only share award plan adds incremental insider economic upside but not at the cost of open-market buying.

4. Board Quality

Three independent directors on an eight-person board. Technically compliant with HKEX Listing Rules (minimum 3 INEDs and at least one-third of the board). Substantively, the question is whether three people can effectively challenge a husband-and-wife control block running a company they built from scratch.

The good news: PwC is the external auditor, the audit committee reviewed the financial statements with no reported qualification or disagreement, the Model Code for securities transactions is in place, and the company self-certifies full CG Code compliance for FY2025. No regulatory action, no going-concern qualification, no profit restatement, no auditor change has surfaced in searchable public coverage. The audit and reporting machinery is working. What is missing is a board that can push back on a strategy that burned HK$3B of shareholders' money on promotion.

5. The Verdict

Grade: C+.

Strongest positives.

• Founder family with ~74% ownership and ~US$1.6B at stake — economic alignment is real, and the controlling shareholder has lost more money in absolute terms than any minority holder.
• Big-4 auditor, clean audit machinery, HKEX-compliant disclosure, no meaningful related-party self-dealing on the balance sheet.
• Dilution is negligible — share awards run through a trust of existing shares, not new issuance.
• Dividend resumed in 2025 at a higher rate than during the profitable 2023-24 years.
• Net cash balance sheet (HK$3.7B cash, no borrowings) removes the financial-distress failure mode that would make governance weaknesses catastrophic.

The real concerns.

• Concentration: husband-and-wife run the company they control. Formal independence exists but cannot check strategy in the vote sense.
• The 2023-2024 capital-allocation episode — a 2.5x increase in promotional spend that destroyed a billion HKD of annual profit — happened on this board's watch, and no one visibly pushed back or left.
• All three INEDs joined at IPO in late 2020 and are approaching the tenure marker where HK listing rules start asking for refreshment.
• The stock has lost ~80% of its IPO value; the controlling family has not signaled confidence with any meaningful open-market buying.
• Non-audit fees (HK$1.1M vs audit HK$3.6M) are modest but worth tracking.

The one thing that would change the grade.

Upgrade to B on visible, substantial insider open-market buying by Pan Dong or Luo Qiuping at current depressed levels, combined with refreshing at least one INED seat with a director bringing genuine consumer-sector challenge (not just a compliance CV). Downgrade to C- on any sign of intercompany loans to the Chairman's family vehicle ZED Group, any change of auditor from PwC, or any walk-back of the dividend now that it has been reset upward.

The read for an investor: this is a founder-led, family-controlled Chinese consumer staple with genuine skin in the game, acceptable disclosure hygiene, and a board that cannot and will not challenge the founders. Alignment protects you on fraud risk; it does not protect you on strategic mistakes. The 2023-2024 promotional splurge is the real governance event in Blue Moon's recent history, and it was a strategic error that the governance structure was not designed to prevent.